Beam TherapeuticsBEAM
Recorded

Beam Therapeutics Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration20 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

AndrzejAnalyst

All right. Welcome, everybody. My name is Andrzej. I am with the equities team here at Guggenheim. I am going to be leading the discussion today, and joining me today is Giuseppe Ciaramella, President of Beam.

AndrzejAnalyst

For those of us who are not very familiar with the company, just overview where the company is and maybe what is currently happening.

Giuseppe CiaramellaPresident

Yes. Beam Therapeutics is a company based in Cambridge, and uses next-generation gene editing technology, primarily called base editing. This technology is a CRISPR editing technology, but has improved the CRISPR technology in two important ways. The first one is it uses the ability of CRISPR to land on a specific spot in the DNA just by changing a small stretch of RNA, which is almost a miracle, I think, sometimes when I think about it. We have eliminated the ability of that protein to make double-stranded breaks, and we feel that that brings a lot of advantages because double-stranded breaks typically create some degree of genotoxicity in the cells, and so we avoid that. What we have also done, we have attached to an additional human enzyme to that Cas9 protein, which is called the deaminase.

Giuseppe CiaramellaPresident

What that enzyme is capable of doing is actually directly on the DNA, changing the chemical structure of one base to another. We can change an A to a G or a C to a T. Obviously, because those pairs are present pretty much in every base pair, we have a lot of flexibility in terms of the edits that we can make. We are now, we are a clinical phase company, and we have four programs in clinical development, spanning from an ex vivo product for sickle cell disease, and then in vivo LNP-based technology for correcting the mutation of several liver-based gene metabolic diseases.

AndrzejAnalyst

Yeah, sort of. Fantastic. There was some data released this morning, exciting data about sickle cell disease.

AndrzejAnalyst

Can you just walk us through that and how is that important?

Giuseppe CiaramellaPresident

Absolutely. I mean, we're extremely pleased to share the fact that the BEACON trial, which is a trial for risto-cel, this is the ex vivo product for sickle cell disease, has met all the primary and secondary endpoint, both in terms of efficacy as well as in safety. We remain on track to file the BLA, the first BLA for the company, as early as the end of this year. We have demonstrated through a variety of different data reporting that risto-cel actually has a very differentiated clinical profile, achieving the highest level of hemoglobin F that has been reported so far, and as a consequence of that, also ensuring that we reduce the hemoglobin S to less than 40%. That in itself is very important.

Giuseppe CiaramellaPresident

We've optimized the manufacturing process very significantly to the point that it is fully automated, and that gives us a much greater reliability in terms of the product that we make, which has been one of the challenges with the existing products like CASGEVY and LYFGENIA, and to some extent contributed to the slow uptake of those programs.

AndrzejAnalyst

You actually have both ex vivo and in vivo approaches. Can you just maybe talk about where each one of those is?

Giuseppe CiaramellaPresident

Yeah. The next more advanced program is the program that we call BEAM-302. This is actually for the correction of the single point mutation that causes alpha-1 antitrypsin deficiency. This is a protein that is made in the liver, but its job is actually to be secreted from the liver, go into the lung, and protect the lung from the unchecked activity of neutrophil elastase. As a consequence of that mutation, this protein misfolds, accumulates in the liver, and so causes toxicity to the liver. But importantly, it doesn't go into the lung to protect the lung, and so these individuals over time develop emphysema. Literally, the density of the lung is reduced very significantly to the point that obviously can lead to premature death. This program is actually now in the pivotal phase.

Giuseppe CiaramellaPresident

We have achieved agreement with the FDA about an accelerated approval path, and so we're moving very steadily through this, and we've announced actually most recently that we expect completion of that pivotal phase in the first half of next year. That's really a very important disease with an unmet medical need. There is only an enzyme replacement therapy that's available for these patients, but that does not lead to cure. It actually slows the progression of the disease, but ultimately does not halt it. We're really the most advanced program for the correction of this disease. The other one is what we call BEAM-301. This is basically the correction of a point mutation called R83C, which causes a mutation in the glucose-6-phosphatase enzyme to the point that individuals affected by this disease, they cannot fast.

Giuseppe CiaramellaPresident

They actually, for night and day, need to go on a very cornstarch, heavy cornstarch diet every two to three hours in order to avoid hypoglycemia, which can be fatal in these individuals. As you can imagine, it starts even from young age, it impacts the entire family. The parents often comment that they cannot sleep because they worry that they may not hear the alarm and not feed their child and then find them dead by the following morning. That's progressing. It's a rare disease. We are now completing dose escalation and going to the 60 mg sort of treatment dose. But we've demonstrated already at the 40 mg that there are two individuals who could actually go without any feeding for 15 hours, as opposed to two hours, which was the maximum before they went to hypoglycemic levels prior to the treatment.

Giuseppe CiaramellaPresident

That's really transformational for the lives of these patients, because now for the first time in their life, they can actually sleep throughout the night and without worrying about a hypoglycemic crisis that could cause them to die.

AndrzejAnalyst

Are those 15 hours limited by the protocol or- Yeah.

Giuseppe CiaramellaPresident

That was the maximum basically that the protocol allowed. Potentially they could have gone even longer, but frankly, who wants to be without food for more than 15 hours?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day